Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer deal
read at Endpoints ↗DealPositive
Eli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment.
The transaction could be worth up to $2.3 billion, reflecting Lilly's strategy of using cash generated from its GLP-1 obesity drugs to fund pipeline expansion.
The partnership adds a potential oncology asset to Lilly's portfolio, aiming to broaden its therapeutic reach beyond metabolic diseases.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor”
read at Endpoints ↗99 words · retrieved Apr 27
comments(0)
5-min edit window · permanent after that